Appili Therapeutics (APLIF)
(Delayed Data from OTC)
$0.02 USD
0.00 (-14.90%)
Updated Sep 23, 2024 01:11 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Appili Therapeutics Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 1 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 7 | 6 | 21 | 12 | 5 |
Income After Depreciation & Amortization | -6 | -6 | -20 | -12 | -5 |
Non-Operating Income | 4 | 0 | 0 | 1 | 1 |
Interest Expense | 1 | 1 | 0 | 0 | 0 |
Pretax Income | -3 | -7 | -20 | -11 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -3 | -7 | -20 | -11 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -3 | -7 | -20 | -11 | -4 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -6 | -20 | -12 | -5 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -6 | -6 | -20 | -12 | -5 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 121.27 | 113.73 | 66.73 | 59.18 | 34.33 |
Diluted EPS Before Non-Recurring Items | -0.02 | -0.06 | -0.30 | -0.18 | -0.12 |
Diluted Net EPS (GAAP) | -0.02 | -0.06 | -0.30 | -0.18 | -0.12 |
Fiscal Year end for Appili Therapeutics Inc falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.01 | 0.36 | 0.25 | 0.01 |
Cost Of Goods | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.01 | 0.36 | 0.25 | 0.01 |
SG&A, R&D, and Dept/Amort Expenses | 2.04 | 1.80 | 1.76 | 1.35 | 1.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.04 | -1.79 | -1.40 | -1.10 | -1.65 |
Non-Operating Income | 1.78 | 1.27 | 1.62 | 0.73 | 0.79 |
Interest Expense | 0.90 | 0.28 | 0.32 | 0.32 | 0.28 |
Pretax Income | -1.16 | -0.80 | -0.11 | -0.70 | -1.14 |
Income Taxes | 0.00 | 0.01 | 0.00 | 0.03 | 0.01 |
Minority Interest | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.16 | -0.81 | -0.11 | -0.73 | -1.15 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.16 | -0.81 | -0.11 | -0.73 | -1.15 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 121.27 | 121.27 | 121.27 | 121.27 | 121.27 |
Diluted EPS Before Non-Recurring Items | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |
Diluted Net EPS (GAAP) | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |